HIV Infection Induces Age-related Changes to Monocytes and Innate Immune Activation in Young Men That Persist Despite Combination Antiretroviral Therapy
Overview
Authors
Affiliations
Objectives: To compare the impact of HIV infection and healthy ageing on monocyte phenotype and function and determine whether age-related changes induced by HIV are reversed in antiretroviral treated individuals.
Design: A cross sectional study of monocyte ageing markers in viremic and virologically suppressed HIV-positive males aged 45 years or less and age-matched and elderly (≥65 years) HIV-uninfected individuals.
Methods: Age-related changes to monocyte phenotype and function were measured in whole blood assays ex vivo on both CD14(++)CD16(-) (CD14(+)) and CD14(variable)CD16(+) (CD16(+)) subsets. Plasma markers relevant to innate immune activation were measured by ELISA.
Results: Monocytes from young viremic HIV-positive males resemble those from elderly controls, and show increased expression of CD11b (P < 0.0001 on CD14(+) and CD16(+)subsets) and decreased expression of CD62L and CD115 (P = 0.04 and 0.001, respectively, on CD14(+) monocytes) when compared with young uninfected controls. These changes were also present in young virologically suppressed HIV-positive males. Innate immune activation markers neopterin, soluble CD163 and CXCL10 were elevated in both young viremic (P < 0.0001 for all) and virologically suppressed (P = 0.0005, 0.003 and 0.002, respectively) HIV-positive males with levels in suppressed individuals resembling those observed in elderly controls. Like the elderly, CD14(+) monocytes from young HIV-positive males exhibited impaired phagocytic function (P = 0.007) and telomere-shortening (P = 0.03) as compared with young uninfected controls.
Conclusion: HIV infection induces changes to monocyte phenotype and function in young HIV-positive males that mimic those observed in elderly uninfected individuals, suggesting HIV may accelerate age-related changes to monocytes. Importantly, these defects persist in virologically suppressed HIV-positive individuals.
HIV and Inflamm-Aging: How Do We Reach the Summit of Healthy Aging?.
Sheets K, Baker J Top Antivir Med. 2025; 32(5):589-596.
PMID: 39765238 PMC: 11737810.
Barger L, El Naggar O, Ha B, Romano G Cancer Metastasis Rev. 2024; 44(1):9.
PMID: 39609320 PMC: 11604825. DOI: 10.1007/s10555-024-10230-6.
Li C, Xu W, Li L, Zhou Y, Yao G, Chen G Adv Sci (Weinh). 2024; 11(48):e2408044.
PMID: 39455287 PMC: 11672322. DOI: 10.1002/advs.202408044.
Inflammation in HIV and Its Impact on Atherosclerotic Cardiovascular Disease.
Obare L, Temu T, Mallal S, Wanjalla C Circ Res. 2024; 134(11):1515-1545.
PMID: 38781301 PMC: 11122788. DOI: 10.1161/CIRCRESAHA.124.323891.
Anderko R, DePuyt A, Bronson R, Bullotta A, Aga E, Bosch R J Immunol. 2024; 212(10):1564-1578.
PMID: 38551350 PMC: 11073922. DOI: 10.4049/jimmunol.2300672.